Table 1.

Clinicopathologic characteristics in relation to KPNA2 and NBS1 immunoreactivity in radical prostatectomy specimens

VariableCharacteristicsNuclear KPNA2 immunoreactivityNuclear NBS1 immunoreactivity
NegativePositivePNegativePositiveP
Zurich TMA
 Age at diagnosis (grouped)<64 y83640.367a141290.428a
≥64 y1147013165
 Gleason score (grouped)5–638180.352a6450.515a
71148514183
8–104836775
 Tumor stage (grouped)pT2a-c134830.332a231860.053a
pT3a-b59504104
pT466012
 Nodal statuspN01541110.799a232380.616a
pN1106014
 Surgical margin statusNegative134860.292a191910.399a
Positive62527108
 Preoperative PSA levels<10 ng/mL81520.906a101201.000a
≥10 ng/mL996613146
Regensburg TMA
 Age at diagnosis (grouped)<64 years58700.437a
≥64 years5554
 Gleason score (grouped)5–638450.675b
72327
8–102336
 Tumor stage (grouped)pT2a-c46440.348b
pT3a-b6479
pT431
 Nodal statuspN092970.491a
pN11724
 Surgical margin statusNegative69700.510a
Positive4454
 Preoperative PSA levels<10 ng/mL54460.080a
≥10 ng/mL5171

NOTE: Bold face representing P < 0.05.

  • aFisher's exact test.

  • bPearson's 2-sided χ2 test.